Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

BlueMountain Capital Management Owns 7.7% Of Newly-Listed Blank-Check Company Global Partner Acquisition Corp. (GPACU)

Page 1 of 2

In a freshly-submitted 13G filing with the U.S. Securities and Exchange Commission, Andrew Feldstein and Stephen Siderow’s BlueMountain Capital Management disclosed owning 1.2 million shares of Global Partner Acquisition Corp. (NASDAQ:GPACU), which represent 7.7% of the newly-listed company’s outstanding common stock.

Andrew Feldstein and Stephen Siderow

BlueMountain Capital is a New York-based activist hedge fund co-established by Stephen Siderow and Andrew Feldstein in 2003. The investment firm, with over $20 billion in assets under management, employs a wide range of investment strategies such as relative value credit, distressed and special situations, long/short equity, and asset-backed finance, to name just a few. Feldstein, the co-founder and current CEO of BlueMountain Capital, had served as a Managing Director and Head of several divisions at J.P. Morgan prior to co-founding his own shop in 2003. It’s worth noting that the hedge fund has registered only one down year since its launch in 2003. As stated by its most recent 13F filing with the SEC, BlueMountain Capital manages a public equity portfolio of $6.10 billion as of March 31, with the fund’s top ten holdings representing 32% of its entire portfolio.

Andrew Feldstein And Stephen Siderow
Andrew Feldstein And Stephen Siderow
Blue Mountain Capital

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 66 percentage points since the end of August 2012. These stocks returned a cumulative of 123.1% vs. 56.6% gain for the S&P 500 Index (read the details). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

Global Partner Acquisition Corp. (NASDAQ:GPACU) operates as a special purpose acquisition company that is seeking to acquire businesses and assets via merger, capital stock exchange, asset acquisition, stock purchase, and/or reorganization. On August 4, the company announced the closing of its initial public offering of 15.53 million shares, which include 2.03 million greenshoe options. The offering was priced at $10.00 per unit, generating gross proceeds of $155.25 million that will eventually be used for the aforementioned business combinations. The units of Global Partner Acquisition began trading on the NASDAQ on July 30, under the ticker symbol “GPACU”. It’s worth noting that each unit consists of one share of the company’s common stock and one warrant, which in turn enables its holders to purchase one-half of one share for $5.75. As soon as the securities comprising the units start trading separately, the common stock of the company and warrants will be listed under the ticker symbols “GPAC” and “GPACW”, correspondingly.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!